TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC ...

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split ...

Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split. What Else: Approved by ...

Shares of TransCode Therapeutics stock opened at $3.85 on Wednesday. The business has a fifty day simple moving average of $395.55 and a 200-day simple moving average of $565.72. TransCode ...

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on TransCode Therapeutics (RNAZ – Research Report) and keeping the price target at $3.00. Emily Bodnar has given her Buy rating ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on ...

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today ...

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TransCode Therapeutics ( (RNAZ)) has provided an update. TransCode Therapeutics has announced a 1-for-33 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...